Login / Signup

Assays and technologies for developing proteolysis targeting chimera degraders.

Xingui LiuXuan ZhangDongwen LvYaxia YuanGuangrong ZhengDaohong Zhou
Published in: Future medicinal chemistry (2020)
Targeted protein degradation by small-molecule degraders represents an emerging mode of action in drug discovery. Proteolysis targeting chimeras (PROTACs) are small molecules that can recruit an E3 ligase and a protein of interest (POI) into proximity, leading to induced ubiquitination and degradation of the POI by the proteasome system. To date, the design and optimization of PROTACs remain empirical due to the complicated mechanism of induced protein degradation. Nevertheless, it is increasingly appreciated that profiling step-by-step along the ubiquitin-proteasome degradation pathway using biochemical and biophysical assays are essential in understanding the structure-activity relationship and facilitating the rational design of PROTACs. This review aims to summarize these assays and to discuss the potential of expanding the toolbox with other new techniques.
Keyphrases
  • small molecule
  • protein protein
  • drug discovery
  • cancer therapy
  • high throughput
  • high glucose
  • diabetic rats
  • structure activity relationship
  • amino acid
  • oxidative stress
  • risk assessment
  • single cell
  • climate change